Belvedere Trading’s PAVmed PAVM Stock Holding History

Belvedere Trading’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5	Closed	-$15K	–	579
2021 Q3	$15K	Buy	+5	New	+$15.8K	﹤0.01%	453

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Belvedere Trading's PAVM Position: Q4 2021 in Review

Belvedere Trading sold out of PAVmed (PAVM) in Q4 2021, closing a stake of 5 shares — an estimated $15K sold.

Belvedere Trading first reported a position in PAVM in Q3 2021 and held it in 1 quarter. The position peaked at $15K in Q3 2021. 105 funds tracked by Wall St. Rank hold PAVM as of Q4 2021.

Belvedere Trading reported no remaining PAVmed position as of Q4 2021 after selling out during the quarter.
Belvedere Trading sold 5 PAVmed shares in Q4 2021, an estimated $15K.
Belvedere Trading first reported a position in PAVmed in Q3 2021 and held it in 1 quarter.
Belvedere Trading's PAVmed position peaked at $15K in Q3 2021.
105 funds tracked by Wall St. Rank held PAVmed as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.